¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£©
¼¶±ð: ²©Ê¿
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-20   

µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£©

µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£© L/LN X{|   
: {Z^ _;Tf  
  Ò»¡¢Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© cGp 6yf  
  1¡¢Co-stimulators (or co-stimulating molecules) R0d|j#vP  
  2¡¢NK-kB ppP?1Il`kb  
  3¡¢Immunoglobulin superfamily c6)zx b  
  4¡¢antigen-presenting cell (APC) .. TjEBp  
  5¡¢death domain 'B6H/d>  
  6¡¢CCR and CXCR ?.ihWbW_  
  7¡¢Lectin (or mitogen) e' VXyf  
  8¡¢Clusters of differentiation, CD) #7ZBbq3=  
  9¡¢B7 family  Z5-'|h$|  
  10¡¢Cytotoxic T lymphocyte, CTL) Lpf=VyqC  
  11¡¢IL-15 and IL-15 receptor (IL-15R) dtl<  
  12¡¢MHC restriction CI'5JOqP  
  13¡¢Affinity-chromatography lGhUfhk  
  14¡¢Cyctosprin A, CsA -h`0v  
  15¡¢Antibody-dependent cell-mediated cytotoxicity, ADCC) L1i> %5:g  
h--bN*}H2  
  ¶þ¡¢¼ò´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© ,_zt? o\  
  1¡¢ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 R"([Y#>m  
  2¡¢ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ +JG"eh&J"H  
  3¡¢ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ tH(#nx8  
_*I6O$/>  
  Èý¡¢ÎÊ´ðÌ⣨25·Ö£© GXVGU-br  
  1¡¢Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ +8I0.,'  
  ѪҺ²¡Ñ§×¨Òµ£º xRN$cZC  
  2¡¢ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»